AstraZeneca shows the largest increase in oncology drug revenue among the top ten revenue generators, with a 3.6–fold increase by 2021.
The other companies’ revenue increases will range from 1.2-fold to 2.4-fold over the same period of time.
Interestingly, Roche—with the largest revenue in 2016, as well as the largest projected for 2021—and AstraZeneca, with the largest growth among the top ten, are both invested in developing immune checkpoint modulators.
Merck while not within the top ten, is forecast to demonstrate a significant increase in oncology revenue by 2021 due mainly to a projected six-fold increase in revenue for its immune checkpoint modulator.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
AbbVie is projected to demonstrate a healthy 3.5-fold increase in revenue in 2021, due primarily to the launch of various targeted therapies over the five-year period.